Doximity Inc. (DOCS:NYSE) delivers digital workflow and AI solutions that connect physicians with essential clinical tools. The company operates at the intersection of healthcare technology and professional networking, serving a market where agentic AI adoption is accelerating rapidly.
Healthcare AI Market Expands as Providers Adopt Workflow Tools
Global spending on agentic AI in healthcare is projected to climb sharply, with one forecast placing the 2025 market at US$1.45 billion and expecting growth to US$19.71 billion by 2034. Fortune Business Insights notes that North America already accounts for more than 45% of this segment. Similar momentum appears in digital health overall, where An August announcement for the Global Health Exhibition highlighted rising investment in AI-driven diagnostics and clinical operations. Broader generative AI applications in clinical trials are also forecast to expand, though SNS Insider published a forecast for the generative AI in clinical trials market that some observers view as overstated; at least one other forecaster using an effectively identical growth rate offers a materially smaller base figure.
Key Investor Takeaways
- Doximity reached more than 85% of U.S. physicians and reported over 800,000 unique active workflow providers in its most recent fiscal quarter.
- Workflow active prescriber growth exceeded 30% year over year while AI Search queries rose more than 25% quarter over quarter.
- Fiscal first-quarter revenue grew 7% to US$156.6 million, though GAAP net income declined to US$24.3 million from the prior-year level.
- Full-year fiscal 2027 revenue guidance was raised to a range of US$671 million to US$681 million.
- Analyst price targets span US$18 to US$47, reflecting a wide range of views on growth sustainability and margin pressure.
- Institutional investors hold nearly 92% of shares, providing a stable but concentrated ownership base.1
Why Doximity Stands Out in Digital Health
The company combines a large physician network with subscription-based marketing solutions and an expanding suite of clinical AI products. Its platform reaches a broad audience across specialties, which supports both pharmaceutical and health-system marketing revenue. Doximity also operates staffing and telehealth modules that leverage the same user base.
Financial Results Show Revenue Growth With Margin Pressure
The company recently released fiscal 2027 first-quarter revenue of US$156.6 million for the three months ended June 30, up 7% from US$145.9 million in the same period a year earlier. GAAP net income fell to US$24.3 million from US$53.3 million, producing a net margin of 15.5%. Non-GAAP net income declined to US$55.0 million while adjusted EBITDA decreased 6% to US$74.8 million. Operating cash flow dropped 32% to US$42.0 million. The company ended the quarter with US$273.6 million in cash and US$414.2 million in marketable securities.
AI Suite and Engagement Metrics Provide Growth Catalysts
Doximity reported that its clinical AI assistant, Doximity Ask, ranked as the top-performing U.S.-based model on the NOHARM benchmark. The company also offers Scribe and Dialer within a free, HIPAA-compliant suite. Co-founder and CEO Jeff Tangney said in the company news release that workflow active prescriber growth exceeded 30% year over year. Doximity's Fall 2026 investor presentation outlines an AI Search offering and notes that AI users represent roughly half of workflow quarterly active users. The presentation further states that 53% of large U.S. pharmaceutical brands have signed marketing agreements with the company.
Analyst Views and Price Targets Reflect Divergent Outlooks
Several firms issued updates in mid-August. Needham maintained a Buy rating with a US$41 target while Piper Sandler raised its target to US$47. Wells Fargo downgraded the stock to Underweight with an US$18 target. Other targets range from US$24 to US$40, illustrating varied expectations around revenue acceleration and profitability.
Guidance and Commercial Reach Set Near-Term Milestones
For the second quarter ending September 30, Doximity guided revenue between US$170 million and US$171 million. Full-year fiscal 2027 revenue guidance now stands at US$671 million to US$681 million with adjusted EBITDA between US$309 million and US$329 million. The company continues to price marketing solutions based on audience size and module mix, reporting strong return-on-investment metrics for both health-system and pharmaceutical customers.
Ownership and Share Structure1
Institutions hold 91.84% of Doximity while management and insiders own 2.81%. The company has 178.25 million shares outstanding and a market capitalization of approximately US$4.74 billion. Its 52-week trading range spans US$17.15 to US$76.51.
Streetwise Ownership Overview*
Doximity Inc. (DOCS:NYSE)
| Date | Old Symbol | Old Shares | New Symbol | New Shares |
|---|---|---|---|---|
| 12/11/99 | DOCSF:NYSE | 1 | DOCS:NYSE | 1 |
Common Questions from Investors
What drove Doximity's fiscal first-quarter revenue growth? Subscription revenue from pharmaceutical and health-system marketing, supported by 107% net revenue retention overall and 112% among top customers, produced the 7% year-over-year increase.
How does Doximity measure AI usage growth? The company tracks AI Search query growth, which rose more than 25% quarter over quarter, and notes that AI users comprise about half of its workflow quarterly active users.
What is the size of Doximity's accessible market? The investor presentation identifies an US$18.5 billion total addressable market across existing segments plus billions more from the new AI Search offering.
How many physicians does the platform reach? Doximity reports access to more than 85% of U.S. physicians across specialties.
What is the current employee count and R&D focus? As of June 30, Doximity employed 885 people, with more than 40% working in research and development.
Retail investors should weigh revenue growth against declining GAAP margins and monitor execution on the new AI Search initiatives. The concentrated institutional ownership base may contribute to share-price volatility around quarterly updates.
| Want to be the first to know about interesting Life Sciences Tools & Diagnostics and Medical Devices investment ideas? Sign up to receive the FREE Streetwise Reports' newsletter. | Subscribe |
Important Disclosures:
- Jordan Nova wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee.
- This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.
- This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.
For additional disclosures, please click here.
1. Ownership and Share Structure Information
The information listed above was updated on the date this article was published and was compiled from information from the company and various other data providers.
